Evolution Of Patent Law In India - Historical Trajectory, Amendments, And Contemporary Challenges
Author: LawSphereX
Category: Intellectual Property
Published:
Updated:
EVOLUTION OF PATENT LAW IN INDIA: HISTORICAL
TRAJECTORY, AMENDMENTS, AND CONTEMPORARY
CHALLENGES
Ashish Chandra Dewanshu, Amity University, Noida
ABSTRACT
Patents represent one of the most significant forms of intellectual property, providing inventors with a temporary monopoly while ensuring that knowledge ultimately enters the public domain. In India, the history of patent law reflects a shift from colonial dependency on British models to the adoption of a uniquely Indian framework that prioritizes access to medicines, public welfare, and industrial growth. The Patents Act, 1970 and its subsequent amendments in 1999, 2002, and 2005—mandated by India’s obligations under the WTO’s TRIPS Agreement—have transformed the country’s patent regime.
This paper traces the historical development of patent law in India, critically analyzes major amendments, examines landmark judicial decisions, and explores contemporary challenges such as traditional knowledge protection, compulsory licensing, and patenting of emerging technologies like biotechnology and artificial intelligence. The paper concludes by offering insights on the future trajectory of Indian patent law in a rapidly evolving global IP ecosystem. Keywords: Patent Law in India; TRIPS Agreement; Compulsory Licensing; Traditional Knowledge Protection; Pharmaceutical Patents
Introduction
The protection of intellectual property rights (IPRs) is indispensable in the modern knowledge economy. Among the various categories of IPRs, patents occupy a pivotal role because they safeguard technological inventions and directly contribute to economic and industrial growth. A patent grants an inventor the exclusive right to exploit an invention for a limited period (20 years in most jurisdictions) in exchange for public disclosure of the invention. 1 Thus, patents operate as a social contract—balancing the private rights of inventors with the collective interest of society. 2 Patents historically emerged in Europe during the late medieval period. The earliest known examples of patents were “letters patent” granted by monarchs to artisans and traders in Italy and England, which conferred monopoly rights. 3 However, these were often misused by monarchs for political or financial gain.
The Statute of Monopolies, 1623, enacted in England, curtailed this abuse by restricting patents to genuine inventions of practical utility4. This statute laid the foundation for the modern understanding of patents and influenced colonial legal systems across the globe, including India. In the Indian context, patents were initially introduced under colonial rule to serve British commercial interests. Medicines, industrial machinery, and consumer goods were imported into India under foreign-controlled monopolies, creating economic dependence and depriving Indian inventors of opportunities5 After independence, India realized that this colonial framework was ill-suited for national development goals. As a result, the Patents Act, 1970 was enacted following the recommendations of the Justice N. Rajagopala Ayyangar Committee (1957).
This legislation marked a significant departure by eliminating product patents for pharmaceuticals and food, thereby encouraging domestic generic drug manufacturing. 6 Today, Indian patent law stands at the intersection of national development priorities and global trade obligations. With the advent of globalization and the WTO’s TRIPS Agreement (1994),
1 WIPO, Understanding Patents (2020), available at https://www.wipo.int/patents/en/
2 Rustom Jal Vakil, Law of Patents (Eastern Book Co., 3rd ed., 2019) 14
3 H.I. Dutton, The Patent System and Inventive Activity during the Industrial Revolution (Manchester Univ. Press, 1984).
4 Statute of Monopolies, 1623 (21 Jac. 1 c. 3)
5 Basheer, S., & Reddy, P., The ‘Efficacy’ of Indian Patent Law
Ironing out the Creases in Section 3(d), 5(2) Script-ed 232 (2008)
6 Report on the Revision of the Patents Law, by Justice N. Rajagopala Ayyangar (1959).
India had to amend its laws to reintroduce product patents while simultaneously safeguarding public health. The judicial decisions of the Supreme Court and High Courts—such as Novartis v. Union of India (2013) and Natco v. Bayer (2012)—have further shaped India’s unique model of balancing innovation incentives with access to affordable medicines.
1. Colonial Origins of Patent Law in India
Patent law in India was a colonial import rather than an indigenous development. The first Indian legislation, Act VI of 1856, was modeled on the British Patent Act of 1852.7 Its objective was to encourage innovation, but in practice, it functioned as a mechanism to safeguard British manufacturers operating in India. The Act granted exclusive rights to inventors for a term of
14 years. However, it was annulled due to lack of approval from the Crown.
In 1859, a new law—Act XV of 1859—was enacted, which allowed inventors exclusive rights to make, sell, and use inventions in India.8 The Act was limited in scope and largely ignored the realities of Indian society. Later, the Inventions and Designs Act, 1888, and the Indian Patents and Designs Act, 1911, consolidated patent protection.9 The 1911 Act remained in force until 1972. Under these colonial laws, India’s pharmaceutical sector was dominated by foreign firms. Essential medicines were imported at high costs, making them unaffordable for most Indians. The patent system operated more as an instrument of foreign monopoly than as a promoter of indigenous innovation.10
2 The Patents Act, 1970
A Paradigm Shift The inadequacies of colonial patent law became increasingly evident in post-independence India. The pharmaceutical industry remained dependent on imports, and foreign firms held sweeping monopolies. In 1957, the Government appointed the Justice Rajagopala Ayyangar Committee to recommend reforms. The committee proposed restricting product patents on
7 Act VI of 1856, India.
8 Act XV of 1859, India
9 The Indian Patents and Designs Act, 1911, Act No. 2 of 1911 (India).
10 R.A. Mashelkar, Intellectual Property Rights and the Third World, 36(3) Journal of the Indian Institute of Science 195 (1996). drugs and chemicals, promoting process patents instead.11 Based on these recommendations, the Patents Act, 1970 was enacted. This Act revolutionized Indian IP law in the following ways: • Product patents abolished for drugs, food, and chemicals—only process patents permitted. • Patent term: 14 years (7 years for drugs and food). • Compulsory licensing provisions introduced to prevent abuse of monopoly. • Section 3 and 5 excluded frivolous inventions, methods of agriculture, atomic energy, and food/pharmaceutical substances.12 The Act empowered Indian companies to manufacture affordable generic medicines by developing alternative processes. This dramatically reduced drug prices and transformed India into the **“pharmacy of the developing world”**13
3. TRIPS Compliance and Patent Amendments in India
India’s membership in the World Trade Organization (WTO) in 1995 marked a watershed moment in its intellectual property regime. By signing the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), India committed to harmonizing its laws with global standards.14 The TRIPS Agreement required all WTO members to provide both process and product patents in all fields of technology, including pharmaceuticals and food. This was a radical shift from India’s 1970 model that had restricted patents to processes only. India negotiated a transitional period of 10 years (1995–2005) to bring its laws into conformity with TRIPS. This period saw three critical amendments to the Patents Act, each addressing different obligations.
11 Report on the Revision of the Patents Law, by Justice N. Rajagopala Ayyangar (1959).
12 The Patents Act, 1970, §§ 3, 5 (India).
13 C.N. Saha & S. Bhattacharya, Intellectual Property Rights in Pharmaceutical Industry, 1 J. Adv. Pharm. Tech. Res. 98 (2011).
14 TRIPS Agreement, Apr. 15, 1994, Marrakesh Agreement Establishing the WTO, Annex 1C, 1869 U.N.T.S.
299.
3.1 Patents (Amendment) Act, 1999
Introduced the “mailbox facility” (Section 5(2)) for product patent applications in pharmaceuticals and agrochemicals. • Allowed Exclusive Marketing Rights (EMRs) for 5 years to applicants who had filed in WTO member states.15 • Represented India’s first step toward TRIPS compliance while still protecting its generic industry.
3.2 Patents (Amendment) Act, 2002
Extended the patent term to 20 years in compliance with TRIPS (Section 53). • Introduced a clearer definition of “inventive step” as “a feature of an invention that involves a technical advance... or has economic significance.”16 • Strengthened compulsory licensing provisions (Sections 84–92). • Allowed publication of patent applications to increase transparency.
3.3 Patents (Amendment) Act, 2005
Marked the most significant reform, introducing product patents in pharmaceuticals, chemicals, and food. • Added Section 3(d): excluded “new forms of known substances” unless they showed enhanced therapeutic efficacy, to prevent “evergreening.”17 • Provided robust pre-grant and post-grant opposition mechanisms. • Recognized public health as a policy priority, consistent with the Doha Declaration on TRIPS and Public Health (2001).18
15 Patents (Amendment) Act, 1999, Act No. 17 of 1999 (India).
16 Patents (Amendment) Act, 2002, Act No. 38 of 2002 (India), § 2(ja).
17 Patents (Amendment) Act, 2005, Act No. 15 of 2005 (India), § 3(d).
18 Doha Declaration on the TRIPS Agreement and Public Health, WT/MIN(01)/DEC/2 (Nov. 14, 2001).
These amendments reflected India’s balancing act: honouring international obligations while safeguarding domestic industry and public health.
4. Landmark Judicial Pronouncements
The Indian judiciary has played a transformative role in shaping patent jurisprudence, often emphasizing public interest and access to medicines.
4.1 Novartis AG v. Union of India (2013)
The Supreme Court rejected Novartis’ application for a patent on Glivec (Imatinib Mesylate) under Section 3(d). The Court held that minor modifications of existing drugs without improved efficacy do not qualify as inventions.19 This judgment strengthened India’s stance against “evergreening.”
4.2 Bishwanath Prasad Radhey Shyam v. Hindustan Metal Industries (1979)
The Court emphasized that patents must involve a genuine inventive step and are granted not for abstract ideas but for concrete industrial application.20
4.3 Merck Sharp & Dohme Corp. v. Glenmark (2016)
The Delhi High Court ruled in favor of Merck on its diabetes drug Sitagliptin, recognizing the importance of patent enforcement in India.21
4.4 Natco Pharma Ltd. v. Bayer Corp. (2012)
The Controller granted India’s first compulsory license for Bayer’s cancer drug Nexavar. Natco was permitted to manufacture the drug at a fraction of Bayer’s price.22 This case demonstrated India’s commitment to access to essential medicines.
4.5 F. Hoffmann-La Roche Ltd. v. Cipla Ltd. (2009)
The Delhi High Court dealt with the conflict between patents and generic entry. While
19 Novartis AG v. Union of India, (2013) 6 SCC 1.
20 Bishwanath Prasad Radhey Shyam v. Hindustan Metal Industries, (1979) 2 SCC 511.
21 Merck Sharp & Dohme Corp. v. Glenmark Pharmaceuticals Ltd., (2016) SCC OnLine Del 1952.
22 Natco Pharma Ltd. v. Bayer Corp., Compulsory License, (2012) IPAB.
recognizing Roche’s patent rights, the Court allowed Cipla to continue manufacturing on grounds of public interest, highlighting India’s pro-access approach.23
4.6 Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2018)
The Supreme Court held that genetically modified (GM) seeds are not patentable under the Patents Act.24 This case underscored India’s cautious approach to biotechnology patents.
4.7 Bajaj Auto Ltd. v. TVS Motor Company Ltd. (2009)
The Court applied the “doctrine of equivalents” to determine patent infringement and highlighted the need for speedy resolution of patent disputes.25
5. Contemporary Challenges in Indian Patent Law
The contemporary landscape of Indian patent law is marked by multiple challenges that test its ability to balance private innovation with public welfare. These challenges are not merely legal but also social, political, and economic, as they touch upon issues of public health, indigenous rights, international trade, and technological innovation.
5.1 Traditional Knowledge & Biopiracy
India is a country rich in traditional knowledge (TK), particularly in fields such as Ayurveda, Siddha, Unani medicine, agriculture, and biodiversity use. However, this indigenous knowledge has often been vulnerable to biopiracy—the misappropriation of biological resources and traditional practices by foreign corporations through the patent system. The most notable cases include: • Turmeric Patent Case (1995): The U.S. Patent Office granted a patent to two Indianorigin scientists at the University of Mississippi for the “use of turmeric in wound healing.” The patent was revoked after the Indian Council of Scientific and Industrial Research (CSIR) provided evidence that turmeric’s medicinal use was centuries-old.26
23 F. Hoffmann-La Roche Ltd. v. Cipla Ltd., (2009) 40 PTC 125 (Del).
24 Monsanto Technology LLC v. Nuziveedu Seeds Ltd., (2018) 2 SCC 13.
25 Bajaj Auto Ltd. v. TVS Motor Company Ltd., JT 2009 (12) SC 103.
26 U.S. Patent No. 5,401,504 (1995).
Neem Patent Case (1994): The European Patent Office granted a patent to W. R. Grace and the U. S. Department of Agriculture for a neem-based fungicide. Following challenges by Indian NGOs and the Government of India, the patent was revoked in 2000. 27 • Basmati Rice Patent (1997): U. S. -based RiceTec Inc. received a patent for “Basmati rice lines and grains. ” India contested this claim, arguing basmati is a geographical indication (GI) linked to India’s cultural heritage. The patent was partially struck down. 28 To combat such cases, India established the Traditional Knowledge Digital Library (TKDL) in 2001. The TKDL documents traditional formulations in Ayurveda, Siddha, and Unani in patent-compatible formats and has been used to prevent over 200 foreign patent claims. 29 However, the TKDL is limited mainly to medicinal knowledge.
Broader challenges persist in protecting traditional agricultural practices, biodiversity-based innovations, and oral knowledge
5.2 Compulsory Licensing & Public Health
Compulsory licensing has become one of the most debated aspects of India’s patent regime. Under Sections 84–92 of the Patents Act, the Controller of Patents may grant a compulsory license (CL) if:
1. A patented invention is not available at a reasonable price,
2. The reasonable requirements of the public are not met, or
3. The invention is not worked in India.30
The most famous case is: • Natco Pharma v. Bayer (2012): The first-ever compulsory license was issued for
27 Case T 0416/01, Neem Oil Extraction, European Patent Office (2000).
28 Shiva, Vandana, Biopiracy
The Plunder of Nature and Knowledge (South End Press, 1997).
29 Anuradha R.V., Traditional Knowledge Digital Library
India’s Answer to Biopiracy, 12 J. World Intell. Prop.
311 (2009).
30 The Patents Act, 1970, §§ 84–92 (India).
Bayer’s cancer drug Nexavar (sorafenib tosylate), priced at ₹2.8 lakh per month. Natco was allowed to sell a generic version at ₹8,800 per month, with 6% royalties to Bayer.31 This decision was hailed internationally as a victory for public health and access to medicines. However, it also drew criticism from developed countries, particularly the U.S., which argued that such measures discourage foreign investment in pharmaceuticals.32 The debate around compulsory licensing became sharper during the COVID-19 pandemic, with calls for CLs on vaccines and treatments. India and South Africa jointly proposed a TRIPS waiver for COVID-related technologies at the WTO in 2020.33 While opposed by developed nations, this proposal highlighted India’s role as a defender of global public health.
5.3 Biotechnology & Genetic Resources
Biotechnology presents one of the most complex areas of patent law. India is a megabiodiversity hotspot, making genetic resources central to innovation in agriculture, medicine, and biotechnology. However, patenting such resources raises ethical and legal dilemmas. • Section 3(j) of the Patents Act excludes “plants and animals in whole or in any part thereof other than microorganisms. ” This means genetically modified organisms (GMOs) and seeds are generally not patentable. 34 • In Monsanto v. Nuziveedu (2018), the Supreme Court held that Monsanto’s patent on Bt Cotton seeds was invalid, as seeds fall within Section 3(j). 35 India also enacted the Biological Diversity Act, 2002, which requires prior approval from the National Biodiversity Authority before accessing biological resources for commercial use.
36 Despite these safeguards, India faces constant pressure from multinational corporations seeking broader biotech patents. Critics argue that overly strict exclusions may discourage
31 Natco Pharma Ltd. v. Bayer Corp., Compulsory License, (2012) IPAB
32 USTR, Special 301 Report (2013)
33 WTO, Waiver from Certain Provisions of the TRIPS Agreement for the Prevention, Containment, and
Treatment of COVID-19, IP/C/W/669 (Oct. 2, 2020).
34 The Patents Act, 1970, § 3(j) (India).
35 Monsanto Technology LLC v. Nuziveedu Seeds Ltd., (2018) 2 SCC 13.
36 The Biological Diversity Act, 2002, Act No. 18 of 2003 (India)
innovation in areas like gene therapy and CRISPR technologies, while others fear erosion of farmers’ rights and biodiversity sovereignty.
5.4 Software, Artificial Intelligence & Digital Patents
In the digital economy, innovation is increasingly software-driven. However, Section 3(k) of the Patents Act excludes “a mathematical or business method or a computer program per se or algorithms” from patentability. 37 This exclusion reflects skepticism toward granting monopolies over abstract software ideas. Yet, with the rise of artificial intelligence (AI), blockchain, and fintech innovations, there is growing debate about whether India should revisit its stance. • The IPO’s 2016 Guidelines for Computer-Related Inventions (CRIs) allowed patents for software combined with hardware, but later revisions rolled back this flexibility. 38 • AI-generated inventions raise further questions: if an AI system “invents,” who is the legal inventor—the programmer, the AI owner, or the AI itself? 39 India has so far taken a conservative approach, focusing on copyright protection for software.
Critics argue this may deter investment in cutting-edge digital industries, while others support the exclusion as a safeguard against monopolization of abstract ideas.
5.5 International Trade Pressures
India’s patent policies, especially in pharmaceuticals, have been a source of friction in international trade. The U.S. frequently places India on its Special 301 “Priority Watch List”, criticizing its use of compulsory licensing, strict standards under Section 3(d), and delays in granting patents.40 Trade negotiations such as the proposed Regional Comprehensive Economic Partnership (RCEP) and India–U.S. Free Trade Agreement have seen pressure on India to adopt “TRIPS-
37 The Patents Act, 1970, § 3(k) (India).
38 IPO, Guidelines for Examination of Computer-Related Inventions (2016).
39 Abbott, Ryan, The Reasonable Robot
Artificial Intelligence and the Law (Cambridge Univ. Press, 2020).
40 USTR, Special 301 Report (2022).
plus” obligations, including data exclusivity and patent term extensions. 41 India has resisted these, arguing they undermine public health and innovation balance. Moreover, India plays a leadership role for developing countries at the WTO, often advocating for a development-oriented interpretation of TRIPS. The Doha Declaration (2001) was largely shaped by India’s insistence that IP rights must not override the right to health. 42 Conclusion The development of patent law in India reflects a continuous balancing act between the protection of private innovation and the pursuit of public welfare.
From its colonial origins, where laws primarily safeguarded foreign monopolies, to the Patents Act, 1970, which prioritized self-reliance and affordable access to medicines, and finally to the TRIPS-driven amendments of the 2000s, India has shaped a patent regime tailored to its socio-economic realities. Judicial decisions such as Novartis v. Union of India and Natco v. Bayer underscore India’s global leadership in resisting practices like “evergreening” while ensuring that essential medicines remain accessible to the public. At the same time, contemporary challenges— biopiracy of traditional knowledge, the complexities of biotechnology, the exclusion of software and AI from patentability, and international trade pressures—continue to test the adaptability of the law.
Ultimately, the Indian patent system demonstrates that intellectual property is not an end in itself but a tool for social and economic progress. Its evolution provides a model for other developing nations seeking to reconcile international obligations with domestic needs, proving that innovation and equity can coexist when guided by principles of justice and public interest. 41 Gopakumar K. M. , India’s Experience with TRIPS-Plus Provisions in Free Trade Agreements, 17 J. World Intell. Prop. 25 (2014).
42 Doha Declaration on TRIPS and Public Health, WT/MIN(01)/DEC/2 (Nov. 14, 2001).